Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | musashi | 0.0027 | 1 | 1 |
Echinococcus multilocularis | NADP dependent isocitrate dehydrogenase | 0.0016 | 0.1996 | 0.1996 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0019 | 0.4151 | 0.5 |
Onchocerca volvulus | 0.0027 | 1 | 0.5 | |
Schistosoma mansoni | ap endonuclease | 0.0019 | 0.4151 | 0.2693 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0019 | 0.4151 | 1 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0019 | 0.4151 | 1 |
Onchocerca volvulus | 0.0027 | 1 | 0.5 | |
Echinococcus multilocularis | NADP dependent isocitrate dehydrogenase | 0.0016 | 0.1996 | 0.1996 |
Schistosoma mansoni | lamin | 0.0027 | 1 | 1 |
Echinococcus granulosus | NADP dependent isocitrate dehydrogenase | 0.0016 | 0.1996 | 0.1996 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0019 | 0.4151 | 0.5 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.0019 | 0.4151 | 0.3482 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0019 | 0.4151 | 0.4151 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0019 | 0.4151 | 1 |
Echinococcus multilocularis | lamin | 0.0027 | 1 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0019 | 0.4151 | 1 |
Echinococcus granulosus | intermediate filament protein | 0.0027 | 1 | 1 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0019 | 0.4151 | 1 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0019 | 0.4151 | 1 |
Schistosoma mansoni | ap endonuclease | 0.0019 | 0.4151 | 0.2693 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0019 | 0.4151 | 0.5 |
Echinococcus multilocularis | isocitrate dehydrogenase 2 (NADP+) | 0.0016 | 0.1996 | 0.1996 |
Schistosoma mansoni | intermediate filament proteins | 0.0027 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0019 | 0.4151 | 0.5 |
Echinococcus granulosus | lamin dm0 | 0.0027 | 1 | 1 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0019 | 0.4151 | 0.5 |
Toxoplasma gondii | exonuclease III APE | 0.0019 | 0.4151 | 1 |
Schistosoma mansoni | lamin | 0.0027 | 1 | 1 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0019 | 0.4151 | 0.5 |
Echinococcus granulosus | lamin | 0.0027 | 1 | 1 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0027 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0027 | 0.9646 | 0.9646 |
Echinococcus multilocularis | isocitrate dehydrogenase | 0.0016 | 0.1996 | 0.1996 |
Brugia malayi | Isocitrate dehydrogenase | 0.0016 | 0.1996 | 0.108 |
Loa Loa (eye worm) | intermediate filament protein | 0.0027 | 1 | 1 |
Loa Loa (eye worm) | isocitrate dehydrogenase | 0.0016 | 0.1996 | 0.1996 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0019 | 0.4151 | 0.5 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0019 | 0.4151 | 0.4151 |
Echinococcus multilocularis | NADP dependent isocitrate dehydrogenase | 0.0016 | 0.1996 | 0.1996 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0019 | 0.4151 | 0.4151 |
Brugia malayi | isocitrate dehydrogenase | 0.0016 | 0.1996 | 0.108 |
Loa Loa (eye worm) | hypothetical protein | 0.0027 | 1 | 1 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0019 | 0.4151 | 1 |
Echinococcus multilocularis | lamin dm0 | 0.0027 | 1 | 1 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0027 | 1 | 1 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0015 | 0.1026 | 0.1026 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.